Skip to content

Correlation of dermatoscopic features of vitiligo with disease activity

A study to sequentially determine the dermatoscopic features of vitiligo and its correlation with disease activity and treatment response

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034757
Enrollment
30
Registered
2021-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Not Applicable: Not applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Department of Dermatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. A clinical diagnosis of vitiligo (segmental or non-segmental type) 2. Active disease defined as VIDA score of 4+ 3. Two independent areas/lesions of of size 2 x 2 cm to 6 x 6 cm showing clinical signs of progressive vitiligo 4. Patients who are yet to be initiated on medical management. A wash off period of 4 weeks for topical and 12 weeks for systemic treatment will be ensured.

Exclusion criteria

Exclusion criteria: 1. Stable disease 2. Patients with only mucosal vitiligo 3. Patients receiving phototherapy or surgical management 4. Patients who refuse to give consent for participation in the study

Design outcomes

Primary

MeasureTime frame
To sequentially determine the dermatoscopic features of vitiligoTimepoint: Baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks

Secondary

MeasureTime frame
1. To correlate the dermatoscopic features with disease activity assessed by means of VIDA and VASI. 2. To correlate the dermatoscopic features of repigmentation with treatment modality used.Timepoint: 4 months

Countries

India

Contacts

Public ContactDr Vinay K

PGIMER Chandigarh

vinay.keshavmurthy@gmail.com8872993222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026